Tele: 561.316.3330
Breaking Medical Device News

Monday, October 18, 2021
HomeHearing AidsWIDEX MOMENT™ Hearing Aids Named CES 2021 Innovation Awards Honoree: Earns Recognition...

WIDEX MOMENT™ Hearing Aids Named CES 2021 Innovation Awards Honoree: Earns Recognition In Health & Wellness and Wearable Technologies Categories

MARKET REPORTS

Global $45 Billion Endoscopy Market Insights & Forecasts to 2025

The global endoscopy market is predicted to reach US$45.28 billion in 2025, growing, at a CAGR of 7.50%, for the duration spanning 2021-2025.

Global Remote Monitoring Devices Market Research Report (2021 to 2026)

Global Remote Monitoring Devices Market size was estimated at USD 1,035.35 million in 2020, is expected to reach USD 1,170.22 million in 2021.

Research Efforts Fuel the Future of Global Obstructive Lung Disease Management Markets – ResearchAndMarkets.com

The "Global Obstructive Lung Disease Management Research Report" report has been added.

Global Electrophysiology Market (2021 to 2026) – Growth, Trends , COVID-19 Impact and Forecasts – ResearchAndMarkets.com

The Electrophysiology Market is expected to register a CAGR of 8.5% during the forecast period.

December 15, 2020

Widex Inc. today announced that it has been named a CES® 2021 Innovation Awards Honoree for the company’s WIDEX MOMENT™ natural-sounding hearing aids. The announcement comes ahead of the first-ever, all-digital CES 2021, happening Jan. 11-14, 2021.

WIDEX MOMENT was selected as an honoree in the CES 2021 Innovation Awards Health & Wellness and Wearable Technologies categories for its groundbreaking solution, which is the first digital hearing aid to incorporate dual artificial intelligence engines to improve real-time listening. Furthermore, the WIDEX MOMENT leverages ZeroDelay technology to reduce the standard sound delay from 7-10 milliseconds seconds to 0.5 milliseconds, creating natural sound that transforms how people with hearing loss experience the world.

“Widex engineers have worked tirelessly over five years to create a unique, natural hearing platform like WIDEX MOMENT,” said Søren Hvidberg Nielsen, President of Widex US. “Hearing aids aren’t only used to amplify speech. For people who benefit from them, they open a far wider aural window onto the lives they want to experience. We are grateful the CES Innovation Awards judges recognized the incredible potential of WIDEX MOMENT as a wearable and wellness device.”

The WIDEX MOMENT utilizes artificial intelligence to create a better sound experience that leads to higher user acceptance. The device’s SoundSense Learn technology adjusts hearing aid settings in two ways using artificial intelligence. First, WIDEX MOMENT learns how users prefer to hear their surroundings by analyzing settings and guiding them through a series of A-B comparisons. Second, they draw from millions of user settings stored in the cloud to help personalize the listening experience.

WIDEX MOMENT hearing aids also include Widex PureSound™ ZeroDelay™ technology, a groundbreaking parallel processing path that all but eliminates latency, resulting in a more natural sound without the “tinny” distortions associated with other hearing aids. By reducing processing latency to just 0.5 milliseconds, Widex ZeroDelay provides users with a new level of clear, natural sound that wasn’t possible in older devices.

The CES Innovation Awards program, owned and produced by the Consumer Technology Association (CTA)®, is an annual competition honoring outstanding design and engineering in consumer technology products across 28 product categories. An elite panel of industry expert judges, including members of the media, designers, engineers and more, reviewed submissions based on innovation, engineering and functionality, aesthetic and design.

spot_img

DON'T MISS

AMRA Medical’s Whole-body MRI Analysis Used in FSHD Clinical Trial Research Network Study for Biomarker Development

To date, the MOVE study has used functional tests as primary outcomes, but recent studies have shown the promise of MRI for FSHD.

Aethlon Medical Announces Peer-Reviewed Publication of Two Case Studies of Critically Ill COVID-19 Patients Treated with the Hemopurifier®

The publication documents two critically ill COVID-19 patients receiving a combined total of nine, six-hour Hemopurifier® treatment sessions.

Koya Medical Presents Positive Interim Data from Randomized Trial Comparing its Dayspring Lymphedema Treatment to Pneumatic Compression

For people with lymphedema, movement is important from both a clinical perspective and a quality-of-life perspective. These data illustrate the Dayspring treatment’s ability to provide that essential movement while still delivering the clinical outcomes we need from compression therapy.

18-Month Below-the-Knee Data with MedAlliance’s SELUTION SLR™ Presented as Late Breaking Trial at VIVA

“We have observed minimal slow-flow phenomena, seen with other paclitaxel drug-eluting balloons.  We have observed several cases of fast wound healing with SELUTION SLR. It is easy to track and deliver. We are looking forward to gaining further clinical experience with this device,” commented Prof. Chong.

Our Sister Publication: Biotechnology News Magazine

By using this website you agree to accept Medical Device News Magazine Privacy Policy